广发养老指数A（000968）基金经理为曹世宇。 截至发稿，曹世宇累计任职时间1年352天，现任基金资产总规模334.65亿元，任职期间最佳基金回报 98.5%， 任职期间最差基金回报-2.74%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 11月28日，太龙药业涨5.37%，截至发稿，报8.04元/股，成交3.39亿元，换手率7.58%，总市值46.14亿 元。 资料显示，河南太龙药业股份有限公司位于河南省郑州市高新技术产业开发区金梭路8号，成立日期 1998年8月31日，上市日期1999年11月5日，公司主营业务涉及医药制造行业中的中药饮片、中成药、化 学药制造业务和医药商业中的药品批发业务以及药品临床前研发服务业务。主营业务收入构成为：药品 制造70.59%，药品研发服务14.71%，药品药材流通14.42%，其他0.28%。 从太龙药业十大流通股东角度 数据显示，广发基金旗下1只基金位居太龙药业十大流通股东。广发养老指数A（000968）三季度减持 26.4 ...

Core Viewpoint - The traditional Chinese medicine industry is undergoing a significant transformation, where only companies that innovate while adhering to core principles will succeed [1] Company Strategy - Tai Long Pharmaceutical focuses on product innovation, supply chain management, channel cultivation, research and development, and brand culture to ensure product quality [1] - The company has established a multi-dimensional growth path centered around its flagship product, the Double Huanglian Oral Liquid, and aims to solidify its position as an "oral liquid expert" [2] Product Development - The Double Huanglian Oral Liquid has evolved into a product family that meets diverse consumer needs, including formulations for children, seniors, and those with specific health conditions [2] - Continuous technological upgrades and clinical trials are being conducted to enhance product quality and extend the product lifecycle [2][6] Market Position - Tai Long Pharmaceutical ranks among the top five in public medical institutions for cold medicine and maintains a strong presence in retail pharmacies [3] - The company is expanding its product line into other therapeutic areas, including cardiovascular and digestive health [3] Dual-Engine Growth - The company leverages traditional techniques alongside modern technology to enhance product quality and traceability, ensuring consumer trust [4] - Tai Long Pharmaceutical is actively participating in the "health and wellness" market, aiming for nationwide expansion through a combination of online and offline strategies [4] Research and Development - The subsidiary, New Leading Pharmaceutical, emphasizes technological innovation and has established a dual-track research strategy [5] - New Leading has developed proprietary technologies in complex formulations and maintains strong partnerships with major pharmaceutical companies [6] Supply Chain Management - Tai Long Pharmaceutical has built over 70 standardized cultivation bases across the country, ensuring a stable supply of high-quality raw materials [7] - The company’s comprehensive supply chain strategy allows it to maintain cost stability amid rising raw material prices [7] Industry Challenges - The traditional Chinese medicine industry is facing challenges such as rising costs, regulatory changes, and the need for innovation [7] - Companies must navigate cost management, quality standards, and innovation to thrive in the evolving market landscape [7] Investment Strategy - The company seeks strategic investors who share a long-term vision and can complement its capabilities, particularly in the health sector [8]

Core Insights - The article highlights the innovative practices of domestic pharmaceutical companies in China, particularly focusing on the advancements made by Realtime Biotech and Tailong Pharmaceutical in the context of the rapidly evolving industry [1][2]. Company Developments - Realtime Biotech, founded by Lin Changqing in 2005, has evolved from an in vitro diagnostic (IVD) company to a biopharmaceutical enterprise, marking a significant transition in its business model [1]. - Tailong Pharmaceutical emphasizes the modernization of traditional Chinese medicine through innovative practices, showcasing the integration of ancient techniques with modern technology in its production processes [1]. Industry Trends - The exploration by Realtime Biotech and Tailong Pharmaceutical reflects the broader trend of innovation within China's biopharmaceutical industry, indicating a shift towards more advanced and diversified medical solutions [2].

Market Overview - The Chinese medicine sector experienced a decline of 0.21% on November 20, with Kanghui Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - *ST Changyao: Closed at 2.83, up 19.92% with a trading volume of 763,900 shares and a turnover of 197 million yuan [1] - Jinhua Co., Ltd.: Closed at 69.8, up 7.15% with a trading volume of 577,400 shares and a turnover of 505 million yuan [1] - Tailong Pharmaceutical: Closed at 7.44, up 3.33% with a trading volume of 344,200 shares and a turnover of 25.2 million yuan [1] - Conversely, Kanghui Co., Ltd. saw a decline of 3.72%, closing at 22.26 with a trading volume of 27,400 shares and a turnover of 61.69 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 143 million yuan from institutional investors, while retail investors saw a net inflow of 133 million yuan [2] - Key stocks with significant capital flow included: - Jinhua Co., Ltd.: Institutional net inflow of 99.64 million yuan, retail net outflow of 79.86 million yuan [3] - Zhongsheng Pharmaceutical: Institutional net inflow of 92.18 million yuan, retail net outflow of 51.91 million yuan [3] - Tailong Pharmaceutical: Institutional net inflow of 25.82 million yuan, retail net outflow of 31.90 million yuan [3]

Macro Strategy - Recent international gold prices are fluctuating at high levels, with domestic jewelry gold prices also remaining elevated. There is a new trend in gold consumption favoring lighter products like gold bars. Short-term gold prices are expected to maintain high volatility. Consumers should pay attention to international gold price fluctuations if investing, and choose purchasing timing based on their budget for wearing needs [2][3] - From January to October, the national general public budget revenue reached 18.649 trillion yuan, a year-on-year increase of 0.8%. The national general public budget expenditure was 22.5825 trillion yuan, a year-on-year increase of 2%. Securities transaction stamp duty revenue was 162.9 billion yuan, a year-on-year increase of 88.1% [2] - By the end of 2024, the total asset scale of urban commercial banks in China is projected to be 60.15 trillion yuan, a 134-fold increase since 1995, accounting for 13.53% of the banking financial institutions, with a market share increase of 8.24 percentage points. The non-performing loan ratio is 1.76%, and the provision coverage ratio is 188.08% [2] Industry and Company Medical Services Industry - The medical and biological sector rose by 3.29%, ranking fifth among the 31 first-level industries. The Shanghai and Shenzhen 300 Index fell by 1.08%, indicating that the medical sector outperformed the index by 4.37 percentage points [6] - The PE (ttm) of the medical services sector is 33.47X, with a PB (lf) of 3.37X. The PE increased by 0.51X and the PB increased by 0.05X compared to the previous week [7][8] - The TIDES CRDMO market is expected to grow significantly, with the global market projected to increase from 2.1 billion USD in 2018 to 5.5 billion USD in 2023, with a CAGR of 20.9%, and further to 37.3 billion USD by 2032, with a CAGR of 23.8%. The Chinese market is expected to grow from 200 million USD in 2018 to 800 million USD in 2023, with a CAGR of 37.1%, and to 6.2 billion USD by 2032, with a CAGR of 25.5% [9] - Investment recommendations for the medical services sector include focusing on high-growth companies in the ADC CDMO and TIDES CDMO areas, as well as companies in the third-party testing laboratories and consumer medical sectors [10] Traditional Chinese Medicine Industry - The traditional Chinese medicine sector rose by 4.08%, ranking third among secondary sub-sectors. Companies such as Te Yi Pharmaceutical and Zhongsheng Pharmaceutical performed well, while others like *ST Changyao and ST Huluwa performed poorly [12] - The PE (ttm) for the traditional Chinese medicine sector is 29.25X, with a PB (lf) of 2.47X, indicating a slight increase from the previous week [13][14] - The market for traditional Chinese medicinal materials is experiencing volatility, with an overall supply surplus due to increased arrivals from new harvests. Recent weather conditions have also impacted harvesting [15] - The steady advancement of centralized procurement in the traditional Chinese medicine industry aims to reduce patient medication costs and shift competition towards cost control and quality standards [16][17] - Investment recommendations for the traditional Chinese medicine sector include focusing on companies with competitive advantages in product quality and cost, as well as those benefiting from national reforms and centralized procurement policies [18][19]

Meeting Details - The fourth temporary shareholders' meeting of Henan Tailong Pharmaceutical Co., Ltd. was held on November 14, 2025, at the company's conference room in Zhengzhou [1] - All 9 current directors attended the meeting, along with the board secretary and other senior executives [2] - The meeting was conducted in compliance with the Company Law and the company's articles of association, using a combination of on-site and online voting [1][2] Resolutions Passed - The profit distribution plan for the first three quarters of 2025 was approved [1] - The proposal to apply for the registration and issuance of medium-term notes was also approved [1] Legal Verification - The meeting was witnessed by Henan Qianwen Law Firm, confirming that the procedures and resolutions were in accordance with relevant laws and regulations [4] Company Changes - The wholly-owned subsidiary, Tongjuntang Pharmaceutical Co., Ltd., completed changes in its legal representative, board members, and business scope, and obtained a new business license from the Zhejiang Provincial Market Supervision Administration [6][7] - The registered capital of Tongjuntang Pharmaceutical Co., Ltd. is RMB 250 million, and it was established on November 30, 2005 [7]

Core Viewpoint - Recently, Tailong Pharmaceutical announced changes in its wholly-owned subsidiary Tongjuntang Pharmaceutical, including alterations in its legal representative, board members, and business scope, along with the completion of relevant registration procedures [2] Group 1 - Tailong Pharmaceutical's subsidiary Tongjuntang Pharmaceutical has undergone changes in its legal representative and board of directors [2] - The company has completed the necessary business registration changes and updated its articles of association [2] - A new business license has been issued by the Market Supervision Administration of Tonglu County, Hangzhou, Zhejiang Province [2]

格隆汇11月14日丨太龙药业(600222.SH)公布,公司全资子公司桐君堂药业有限公司根据经营发展需要对 其法定代表人、董监高人员以及经营范围进行了变更，同时完成上述工商变更登记及《公司章程》的相 关备案登记手续，并取得浙江省杭州市桐庐县市场监督管理局换发的《营业执照》。 ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-060 河南太龙药业股份有限公司 关于全资子公司完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，河南太龙药业股份有限公司（以下简称"公司"）全资子 公司桐君堂药业有限公司根据经营发展需要对其法定代表人、董监高 人员以及经营范围进行了变更，同时完成上述工商变更登记及《公司 章程》的相关备案登记手续，并取得浙江省杭州市桐庐县市场监督管 理局换发的《营业执照》，具体情况如下： | 变更事项 | 变更前 | 变更后 | | --- | --- | --- | | 法定代表 | 李金宝 | 胡志权 | | 人 | | | | 高级管理 | 李金宝（董事长）、李景亮（董事）、赵 | 胡志权（董事长）、李景亮（董事）、赵海 | | 人员备案 | 海林（董事）、苏风山（监事） 许可项目：药品批发；第三类医疗器械经 | 林（董事） 许可项目：药品批发；第三类医疗器械经营； | | | 营；食品经营（销售预包装食品）；道路 | 道路货物 ...

本次会议是否有否决议案：无 一、 会议召开和出席情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (一)股东会召开的时间：2025 年 11 月 14 日 证券代码：600222 证券简称：太龙药业 公告编号：2025-059 河南太龙药业股份有限公司 2025年第四次临时股东会决议公告 (二)股东会召开的地点：郑州高新技术产业开发区金梭路 8 号公司一楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 272 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 150,902,963 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 27.2918 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长王荣涛先生主持，以现场投票和网络 投票相结合的方式进行表决。本次股东会的召集、召开及表决方式符合《 ...